These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1689892)

  • 21. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient.
    Cox TH; Baillie GM; Baliga P
    Pharmacotherapy; 1997; 17(6):1328-30. PubMed ID: 9399620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early trials with FK 506 as primary treatment in liver transplantation.
    Todo S; Fung JJ; Demetris AJ; Jain A; Venkataramanan R; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):13-6. PubMed ID: 1689886
    [No Abstract]   [Full Text] [Related]  

  • 23. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
    Fung JJ; Todo S; Tzakis A; Demetris A; Jain A; Abu-Elmaged K; Alessiani M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):14-21. PubMed ID: 1703682
    [No Abstract]   [Full Text] [Related]  

  • 24. FK 506--a promise of good things to come?
    Neuberger J
    Hepatology; 1991 Jun; 13(6):1259-60. PubMed ID: 1711005
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of FK 506 on renal function after liver transplantation.
    McCauley J; Fung J; Jain A; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):17-20. PubMed ID: 1689887
    [No Abstract]   [Full Text] [Related]  

  • 27. FK-506 and haemolytic uraemic syndrome.
    Brown Z; Neild GH
    Lancet; 1990 Feb; 335(8686):412. PubMed ID: 1689442
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful switch-over administration of intravenous-to-oral tacrolimus after isolated living-donor liver transplantation in a child with ultra short gut syndrome.
    Koike Y; Uchida K; Kusunoki M
    Transpl Int; 2012 Feb; 25(2):e29-30. PubMed ID: 22211826
    [No Abstract]   [Full Text] [Related]  

  • 29. Interspecies comparison of the immunosuppressive efficacy and safety of FK 506.
    Thomson AW
    Transplant Proc; 1990 Feb; 22(1):100-5. PubMed ID: 1689883
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral glucose tolerance test in liver recipients treated with FK 506.
    Mieles L; Todo S; Fung JJ; Jain A; Furukawa H; Susuki M; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):41-3. PubMed ID: 1689894
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of FK 506: preclinical and clinical studies.
    Venkataramanan R; Jain A; Cadoff E; Warty V; Iwasaki K; Nagase K; Krajack A; Imventarza O; Todo S; Fung JJ
    Transplant Proc; 1990 Feb; 22(1):52-6. PubMed ID: 1689899
    [No Abstract]   [Full Text] [Related]  

  • 32. Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient.
    Tsubo T; Iwakawa T; Muraoka M; Ishihara H; Matsuki A
    ASAIO J; 1997; 43(4):363-4. PubMed ID: 9242954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC; Theilmann L
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract]   [Full Text] [Related]  

  • 35. Renal transplantation in baboons under FK 506.
    Imventarza O; Todo S; Eiras G; Ueda Y; Furukawa H; Wu YM; Zhu Y; Oks A; Demetris J; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):64-5. PubMed ID: 1689903
    [No Abstract]   [Full Text] [Related]  

  • 36. Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group.
    Transpl Int; 1994; 7 Suppl 1():S247-51. PubMed ID: 11271216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506.
    Murase N; Kim DG; Todo S; Cramer DV; Fung J; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):74-5. PubMed ID: 1689906
    [No Abstract]   [Full Text] [Related]  

  • 38. Expressive dysphasia possibly related to FK506 in two liver transplant recipients.
    Reyes J; Gayowski T; Fung J; Todo S; Alessiani M; Starzl TE
    Transplantation; 1990 Dec; 50(6):1043-5. PubMed ID: 1701571
    [No Abstract]   [Full Text] [Related]  

  • 39. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent.
    Staschak S; Wagner S; Block G; Van Thiel DH; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):47-9. PubMed ID: 1689896
    [No Abstract]   [Full Text] [Related]  

  • 40. [FK-506. A new immunosuppressive drug].
    MacLeod AM; Thomson AW
    Medicina (Firenze); 1990; 10(3):329-32. PubMed ID: 1706817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.